Capital Fund Management (CFM)’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.1M Sell
53,145
-28,153
-35% -$4.84M 0.04% 586
2026
Q1
$13.7M Sell
81,298
-52,603
-39% -$9M 0.06% 431
2025
Q4
$22.6M Buy
+133,901
New +$21.7M 0.06% 441
2025
Q3
Sell
-92,567
Closed -$12.6M 2560
2025
Q2
$11.7M Sell
92,567
-48,619
-34% -$5.97M 0.03% 668
2025
Q1
$18.1M Buy
141,186
+23,912
+20% +$3.24M 0.05% 476
2024
Q4
$15.5M Buy
+117,274
New +$16.5M 0.04% 564
2023
Q4
Sell
-61,101
Closed -$7.45M 2198
2023
Q3
$7.47M Buy
+61,101
New +$7.77M 0.03% 745
2023
Q1
Sell
-34,581
Closed -$4.53M 1647
2022
Q4
$4.54M Buy
34,581
+16,253
+89% +$2.1M 0.03% 647
2022
Q3
$2.14M Buy
18,328
+7,650
+72% +$950K 0.02% 843
2022
Q2
$1.26M Buy
+10,678
New +$1.27M 0.01% 988
2021
Q4
Sell
-17,107
Closed -$2.65M 1712
2021
Q3
$2.77M Hold
17,107
0.02% 795
2021
Q2
$2.8M Buy
+17,107
New +$2.64M 0.02% 800
2020
Q4
Sell
-45,251
Closed -$6.47M 1408
2020
Q3
$6.13M Buy
+45,251
New +$6.14M 0.08% 296
2019
Q3
Sell
-28,616
Closed -$3.12M 1765
2019
Q2
$3.12M Buy
+28,616
New +$3.04M 0.03% 667
2018
Q2
Sell
-5,083
Closed -$544K 2113
2018
Q1
$543K Sell
5,083
-6,372
-56% -$706K ﹤0.01% 1433
2017
Q4
$1.22M Buy
+11,455
New +$1.22M 0.01% 1143
2017
Q3
Sell
-103,551
Closed -$11.1M 1620
2017
Q2
$10.7M Buy
103,551
+48,354
+88% +$4.76M 0.09% 286
2017
Q1
$5.4M Buy
55,197
+5,391
+11% +$516K 0.05% 445
2016
Q4
$4.41M Buy
+49,806
New +$4.53M 0.04% 533
2016
Q3
Sell
-24,006
Closed -$2.28M 1669
2016
Q2
$2.06M Buy
+24,006
New +$2.15M 0.02% 725
2015
Q4
Sell
-85,200
Closed -$9.25M 1634
2015
Q3
$8.62M Buy
+85,200
New +$10.2M 0.1% 270
2015
Q2
Sell
-32,433
Closed -$3.88M 1567
2015
Q1
$3.71M Buy
32,433
+14,001
+76% +$1.54M 0.05% 422
2014
Q4
$1.86M Sell
18,432
-6,624
-26% -$644K 0.02% 698
2014
Q3
$2.29M Buy
+25,056
New +$2.2M 0.03% 636

Other funds holding IBB

Capital Fund Management (CFM)'s IBB Position: Q2 2026 in Review

Capital Fund Management (CFM) reduced its iShares Biotechnology ETF (IBB) stake by 35% in Q2 2026, selling an estimated $4.84M and leaving 53,145 shares worth $10.1M. The position accounts for 0.04% of the portfolio, ranked #586.

Capital Fund Management (CFM) first reported a position in IBB in Q3 2014 and has held it in 24 quarters since. The position peaked at $22.6M in Q4 2025. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Capital Fund Management (CFM) held 53,145 shares of iShares Biotechnology ETF worth $10.1M as of Q2 2026.
  • Capital Fund Management (CFM) sold 28,153 iShares Biotechnology ETF shares in Q2 2026, an estimated $4.84M.
  • iShares Biotechnology ETF made up 0.04% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #586 holding.
  • Capital Fund Management (CFM) first reported a position in iShares Biotechnology ETF in Q3 2014 and has held it in 24 quarters since.
  • Capital Fund Management (CFM)'s iShares Biotechnology ETF position peaked at $22.6M in Q4 2025.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.